OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
26/03/2026
Voltar para busca
Dado oficial do USPTO
ACELLYTRON THERAPEUTICS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
25
Atualização mais recente
03/04/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 35, 42, 44
Data de depósito
08/03/2024
Data de registro
20/05/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
20/05/2025
Última transação
03/04/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
03
Localização do titular
CN
Examinador
JACKSON, STEVEN W
Unidade examinadora
L70
Localização atual
FILE REPOSITORY (FRANCONIA)
Descrição da marca
The mark consists of the stylized wording "ACELLYTRON THERAPEUTICS" with a double strand DNA inside the stylized letter "O".
Titulares e representantes
Titulares
Wuxi Biologics (Shanghai) Co., Ltd.
Representantes
Michael T. Smith Birch Stewart Kolasch & Birch LLP
Classificação técnica
Classes Nice
Classe 5Classe 35Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Chemical-pharmaceutical preparations for the treatment of autoimmuneneurodegenerativemetabolicviral and infectious diseasesfor the treatment of cancer; biochemical medicines for the treatment of autoimmuneneurodegenerativemetabolicviral and infectious diseasesfor the treatment of cancer; vaccine preparations; influenza vaccine; chemotherapeutics; stem cells for medical purposes; medicines for human purposes for the treatment of autoimmuneneurodegenerativemetabolicviral and infectious diseasesfor the treatment of cancer; drugs for medical purposesmedicines for the treatment of autoimmuneneurodegenerativemetabolicviral and infectious diseasesfor the treatment of cancer; pharmaceutical preparations for the treatment of autoimmuneneurodegenerativemetabolicviral and infectious diseasesfor the treatment of cancer; drugs for treatment of cancer; medical preparation for treating diseases and disorders related to the immune system; biological agentbiological preparations for treating cancer; pharmaceutical preparations for the prevention and treatment of cancer; living cells for medical use; medical cell inhibitor for inhibiting the growth of cancer cells; reagents for medical purposes; anticancer agent; diagnostic reagents for medical purposes; pharmaceutical preparationstumor suppressor; cells for medical use; dietetic infusionssugarfoodsbeverages substances adapted for medical use; biological preparations for veterinary purposes for the treatment of autoimmuneneurodegenerativemetabolicviral and infectious diseasesfor the treatment of cancer
Classe 35
Online advertising on a computer network; advertising services; publicity agents; dissemination of advertising and advertising matter in the nature of flyersprospectusesbrochuresleaflets and samples; providing commercial information and advice for consumers in the choice of products and services; organization of exhibitions and trade fairs for commercial or advertising purposes; import-export agency services; marketing; sponsorship search; retail store services for pharmaceuticalveterinary and sanitary preparations and medical supplies; wholesale store services for pharmaceuticalveterinary and sanitary preparations and medical supplies
Classe 42
Research and development of new products for others; technological research in the field of chemical and biological medicaments; chemical analysis; biochemical research and analysis; research and development in the field of pharmaceutical preparations; medical research service; research and development of services in the field of antibodies; stem cell research services; medical research; medical and scientific researchconducting clinical trials for others; biological research; computer programming in the field of medical aspects
Classe 44
Preparation of prescriptions by pharmacists; stem cell therapy services; medical clinic services; providing medical information; DNA screening for medical purposes; medical analysis services for the diagnosis of cancer; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical screening; health care; medical assistance
Publicações
Histórico de despachos e eventos da marca no USPTO.
25 publicações encontradas
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
09/03/2026
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
09/03/2026
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
08/01/2026
FICS
FINAL DISPOSITION NOTICE SENT TO IB
19/12/2025
FIMP
FINAL DISPOSITION PROCESSED
19/12/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
21/08/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
20/05/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
20/05/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/04/2025
PUBO
PUBLISHED FOR OPPOSITION
01/04/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
26/03/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/03/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/03/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/03/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/03/2025
RFNT
REFUSAL PROCESSED BY IB
17/11/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
30/10/2024
RFRR
REFUSAL PROCESSED BY MPU
30/10/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
25/10/2024
CNRT
NON-FINAL ACTION WRITTEN
24/10/2024
DOCK
ASSIGNED TO EXAMINER
17/10/2024
MAFR
APPLICATION FILING RECEIPT MAILED
16/10/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
16/10/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
10/10/2024
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ACELLYTRON THERAPEUTICS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.